EMP1-positive cells found guilty of metastatic relapse in colorectal cancer

Metastatic recurrence develops in 30%–40% of colorectal cancer (CRC) patients in the years that follow surgical removal of the primary tumor. In a recent issue of Nature, Cañellas-Socias et al. identify a distinct population of CRC cells, marked with epithelial membrane protein 1 (EMP1), accountable...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Developmental cell 2022-12, Vol.57 (24), p.2673-2674
Hauptverfasser:	Gvozdenovic, Ana, Aceto, Nicola
Format:	Artikel
Sprache:	eng
Schlagworte:	Colorectal Neoplasms - pathology Humans Neoplasm Proteins - metabolism Receptors, Cell Surface - metabolism Recurrence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Metastatic recurrence develops in 30%–40% of colorectal cancer (CRC) patients in the years that follow surgical removal of the primary tumor. In a recent issue of Nature, Cañellas-Socias et al. identify a distinct population of CRC cells, marked with epithelial membrane protein 1 (EMP1), accountable for metastatic relapse. Metastatic recurrence develops in 30%–40% of colorectal cancer (CRC) patients in the years that follow surgical removal of the primary tumor. In a recent issue of Nature, Cañellas-Socias et al. identify a distinct population of CRC cells, marked with epithelial membrane protein 1 (EMP1), accountable for metastatic relapse.
ISSN:	1534-5807 1878-1551
DOI:	10.1016/j.devcel.2022.11.017